Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01)

archived

Purpose. The aim of this Funding Opportunity Announcement (FOA) issued by the National Institute of Mental Health (NIMH), National Institutes of Health (NIH), is to support research focused on accelerating basic and translational scientific discoveries with a plan to advance drug therapeutics for HIV-Associated Neurocognitive Disorders (HAND). Recent clinical observations indicate that over 50% of HIV infected patients manifest HAND despite receiving highly active antiretroviral therapy (HAART). These clinical observations inform the need to obtain a better understanding of HAND and to develop novel therapeutic drug candidates to prevent or interfere with progression of HAND. Applicants are invited to develop a multidisciplinary program with a minimum of three highly integrated research projects and one Administrative Core focused on research and development of novel therapeutics for HAND. At least one component (research project) may be derived from industry (i.e., pharmaceutical, chemical, bioengineering or biotechnological companies). A Scientific Advisory Panel (SAP) for each award under this FOA will be constituted within 6 months of the award. Mechanism of Support. This FOA will utilize the NIH Program Project (P01) award mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.

High